OTC dandruff monograph
This article was originally published in The Rose Sheet
Executive Summary
The final monograph for OTC dandruff, seborrheic dermatitis and psoriasis drug products is being amended to include the combination of 1.8% coal tar solution and 1.5% menthol in a shampoo drug product to control dandruff, FDA announces in a March 6 Federal Register notice. The regulation is effective April 5. The agency solicited comments on the proposed amendment in late 2005, but did not receive any responses (1"The Rose Sheet" Dec. 12, 2005, p. 6)...
You may also be interested in...
FDA Proposes Coal Tar/Menthol Addition To OTC Dandruff Monograph
The final monograph for OTC dandruff, seborrheic dermatitis and psoriasis drug products would be amended to include a specific combination of coal tar and menthol under a proposed rule published by FDA in the Federal Register Dec. 9
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.